CARA - Cara Therapeutics, Inc.
IEX Last Trade
0.42
-0.009 -2.071%
Share volume: 6,096
Last Updated: Fri 27 Dec 2024 08:29:25 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.90%
PREVIOUS CLOSE
CHG
CHG%
$0.43
-0.01
-2.03%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-08 | 2022-11-07 | 2023-03-06 | 2023-05-15 | 2023-08-07 | 2023-11-13 | 2024-03-06 | 2024-05-13 | |
| Assets | |||||||||
| Total Assets | 226.572 M | 213.509 M | 182.237 M | 153.276 M | 134.389 M | 115.338 M | 125.844 M | 90.099 M | |
| Current Assets | 176.166 M | 186.780 M | 168.910 M | 142.659 M | 124.736 M | 100.603 M | 116.158 M | 81.225 M | |
| Inventories | 3.460 M | 1.835 M | 2.383 M | 3.515 M | 3.420 M | 3.266 M | 2.821 M | 2.741 M | |
| Other Current Assets | 6.026 M | 18.562 M | 16.267 M | 17.195 M | 14.976 M | 12.658 M | 8.154 M | 5.790 M | |
| Short Term Investments | 6.026 M | 18.562 M | 16.267 M | 17.195 M | 14.976 M | 12.658 M | 8.154 M | 5.790 M | |
| Total Receivables | 9.168 M | 10.771 M | 4.453 M | 7.258 M | 11.241 M | 5.730 M | 4.017 M | 2.921 M | |
| Current Cash | 157.512 M | 155.612 M | 145.399 M | 114.283 M | 94.691 M | 78.541 M | 100.758 M | 69.773 M | |
| Total Non-current Assets | 50.406 M | 26.729 M | 13.327 M | 10.617 M | 9.653 M | 14.735 M | 9.686 M | 8.874 M | |
| Property Plant Equipment | 549.000 K | 487.000 K | 426.000 K | 368.000 K | 308.000 K | 1.380 M | 3.322 M | 3.548 M | |
| Other Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 226.572 M | 213.509 M | 182.237 M | 153.276 M | 134.389 M | 115.338 M | 125.844 M | 90.099 M | |
| Total liabilities | 22.150 M | 28.689 M | 23.458 M | 16.678 M | 25.457 M | 29.696 M | 68.759 M | 60.296 M | |
| Total current liabilities | 21.167 M | 28.192 M | 23.458 M | 16.678 M | 25.457 M | 22.881 M | 25.592 M | 15.095 M | |
| Accounts Payable | 9.740 M | 15.218 M | 9.604 M | 4.424 M | 12.122 M | 7.978 M | 11.583 M | 4.978 M | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 37.079 M | 38.376 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 37.079 M | 38.376 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 204.422 M | 184.820 M | 158.779 M | 136.598 M | 108.932 M | 85.642 M | 57.085 M | 29.803 M | |
| Common stock | 53.615 M | 53.726 M | 53.766 M | 53.872 M | 54.003 M | 54.236 M | 54.486 M | 54.588 M | |
| Retained earnings | -512.713 M | -535.893 M | -566.232 M | -592.897 M | -624.376 M | -652.408 M | -684.745 M | -715.441 M |